Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2006

01.01.2006 | Short Communication

Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients

verfasst von: Kishor M. Wasan, Joyce C. Wong, Traci Corr, Sheila Pritchard

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose: The objective of this study was to determine if total plasma and lipoprotein cholesterol (C) and triglyceride (TG) concentrations could predict the degree of nephrotoxicity caused by the antifungal agent amphotericin B (AmpB); and to use the average amount of potassium supplementation received daily as a indicator of nephrotoxicity in pediatric oncology patients. Patients and methods: Plasma samples from 18 patients (ages<17 years) who were receiving AmpB due to suspected or confirmed fungal infection at British Columbia Children’s Hospital were analyzed for lipid concentrations. The high density lipoprotein (HDL) fractions were separated by precipitation; total (TOT) plasma and fraction C and TG concentrations were measured by enzymatic colorimetric assays; and low density lipoprotein (LDL) C levels were determined by Friedewald’s formula. Changes in serum creatinine levels from baseline and amounts of potassium supplementation were used as indicators of nephrotoxicity; both were obtained from patients’ medical charts. Pearson correlation coefficients (r) were determined and considered significant if P<0.05. Results: The total cumulative AmpB dose, adjusted for weight, does not seem to predict AmpB-induced nephrotoxicity. Positive but relatively weak correlations were found between total potassium supplementation and LDL C (r=0.489, P<0.02); and TOT C (r=0.551, P<0.01). In addition, a positive but relatively weak correlation between the average amount of potassium supplementation per day above baseline and HDL C (r=0.407; P<0.02) was observed. Conclusion: Differences in total plasma and LDL cholesterol concentrations may be used as predictors of AmpB-induced nephrotoxicity in pediatric oncology patients.
Literatur
1.
Zurück zum Zitat Rothon DA, Mathias RG, Schechter MT (1994) Prevalence of HIV infection in provincial prisons in British Columbia. Can Med Assoc J 151:781–787 Rothon DA, Mathias RG, Schechter MT (1994) Prevalence of HIV infection in provincial prisons in British Columbia. Can Med Assoc J 151:781–787
2.
Zurück zum Zitat Meyer RD (1992) Current role of therapy with amphotericin B. Clin Infect Dis 14:S154–S168PubMed Meyer RD (1992) Current role of therapy with amphotericin B. Clin Infect Dis 14:S154–S168PubMed
3.
Zurück zum Zitat Dunagan WC, Powderly WG (1989) Antimicrobials and Infectious Diseases. In: Dunagan WC, Ridner ML (eds) Manual of medical therapeutics. Little, Brown and Company, Boston, pp 251–252 Dunagan WC, Powderly WG (1989) Antimicrobials and Infectious Diseases. In: Dunagan WC, Ridner ML (eds) Manual of medical therapeutics. Little, Brown and Company, Boston, pp 251–252
4.
Zurück zum Zitat Clements JS, Peacock JE (1990) Amphotericin B revisited: reassessment of toxicity. Am J Med 88:22N–27NPubMed Clements JS, Peacock JE (1990) Amphotericin B revisited: reassessment of toxicity. Am J Med 88:22N–27NPubMed
5.
Zurück zum Zitat Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, Branch RA (1991) Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 40:302–308PubMedCrossRef Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, Branch RA (1991) Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 40:302–308PubMedCrossRef
6.
Zurück zum Zitat Koren G, Lau A, Klein J, Golas C, Bologa-Campeanu M, Soldin S, MacLeod SM, Prober C (1988) Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr 113:559–563PubMedCrossRef Koren G, Lau A, Klein J, Golas C, Bologa-Campeanu M, Soldin S, MacLeod SM, Prober C (1988) Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr 113:559–563PubMedCrossRef
7.
Zurück zum Zitat Hoeprich PD (1992) Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 14:S114–S119PubMed Hoeprich PD (1992) Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 14:S114–S119PubMed
8.
Zurück zum Zitat Nicholl T, Phillips P, Jewesson PJ (1994) Amphotericin B use in a major acute care hospital. Clin Ther 16:28–40PubMed Nicholl T, Phillips P, Jewesson PJ (1994) Amphotericin B use in a major acute care hospital. Clin Ther 16:28–40PubMed
9.
Zurück zum Zitat Anderson RJ, Schrier RW (1991) Acute renal failure. In: Wilson JD, Braunwald E, Isselbacher KJ et al (eds) Principles of internal medicine, 12th edn. McGraw Hill, New York, pp 1144–1150 Anderson RJ, Schrier RW (1991) Acute renal failure. In: Wilson JD, Braunwald E, Isselbacher KJ et al (eds) Principles of internal medicine, 12th edn. McGraw Hill, New York, pp 1144–1150
10.
Zurück zum Zitat Wasan KM, Kennedy AL, Cassidy SM et al (1998) The pharmacokinetics, serum lipoprotein and tissue distribution and renal toxicity of amphotericin B (AmpB) and amphotericin B lipid complex (ABLC) in a hypercholesterolemic rabbit model: single dose studies. Antimicrob Agents Chemother 42:3146–3152PubMed Wasan KM, Kennedy AL, Cassidy SM et al (1998) The pharmacokinetics, serum lipoprotein and tissue distribution and renal toxicity of amphotericin B (AmpB) and amphotericin B lipid complex (ABLC) in a hypercholesterolemic rabbit model: single dose studies. Antimicrob Agents Chemother 42:3146–3152PubMed
11.
Zurück zum Zitat Wasan KM, Conklin JS (1997) Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin Infect Dis 24:78–80PubMed Wasan KM, Conklin JS (1997) Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin Infect Dis 24:78–80PubMed
12.
Zurück zum Zitat Wasan KM, Brazeau GA, Keyhani A et al (1993) Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 37:246–250PubMed Wasan KM, Brazeau GA, Keyhani A et al (1993) Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 37:246–250PubMed
13.
Zurück zum Zitat Wasan KM, Morton RE, Rosenblum MG et al (1994) Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 83:1006–1010PubMedCrossRef Wasan KM, Morton RE, Rosenblum MG et al (1994) Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 83:1006–1010PubMedCrossRef
14.
Zurück zum Zitat Wasan KM, Rosenblum MG, Cheung L et al (1994) Influence of lipoprotein-associated amphotericin B on its renal cytotoxicity and antifungal activity. Antimicrob Agents Chemother 38:223–228PubMed Wasan KM, Rosenblum MG, Cheung L et al (1994) Influence of lipoprotein-associated amphotericin B on its renal cytotoxicity and antifungal activity. Antimicrob Agents Chemother 38:223–228PubMed
15.
Zurück zum Zitat Wasan KM, Cassidy SM (1998) Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci 87:411–424CrossRefPubMed Wasan KM, Cassidy SM (1998) Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci 87:411–424CrossRefPubMed
16.
Zurück zum Zitat Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM (2001) Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother 45:1184–1191CrossRefPubMed Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM (2001) Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother 45:1184–1191CrossRefPubMed
17.
Zurück zum Zitat Luber AD, Maa L, Lam M et al (1999) Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 43:267–271CrossRefPubMed Luber AD, Maa L, Lam M et al (1999) Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 43:267–271CrossRefPubMed
18.
Zurück zum Zitat Fisher MA, Talbot GH, Maislin G et al (1989) Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 87:547–552PubMedCrossRef Fisher MA, Talbot GH, Maislin G et al (1989) Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 87:547–552PubMedCrossRef
19.
Zurück zum Zitat Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686–693CrossRefPubMed Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686–693CrossRefPubMed
20.
Zurück zum Zitat Miller RP, Bates JH (1969) Amphotericin B toxicity: a follow-up report of 53 patients. Ann Intern Med 71:1089–1095PubMed Miller RP, Bates JH (1969) Amphotericin B toxicity: a follow-up report of 53 patients. Ann Intern Med 71:1089–1095PubMed
Metadaten
Titel
Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients
verfasst von
Kishor M. Wasan
Joyce C. Wong
Traci Corr
Sheila Pritchard
Publikationsdatum
01.01.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-0011-x

Weitere Artikel der Ausgabe 1/2006

Cancer Chemotherapy and Pharmacology 1/2006 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.